Abbreviation	Description
NETs	neuroendocrine tumors
NECs	neuroendocrine carcinomas
ANENs	appendiceal neuroendocrine neoplasms
ANETs	Appendiceal neuroendocrine tumors
ANECs	appendiceal neuroendocrine carcinoma
MiNENs	mixed neuroendocrine-non-neuroendocrine neoplasms
pNETs	pancreatic neuroendocrine tumors
GEP-NENs	gastroenteropancreatic neuroendocrine neoplasms
G1	low grade (Grade 1)
G2	intermediate grade (Grade 2)
G3	high grade (Grade 3)
WHO	World Health Organization
MI	mitotic index
CgA	Chromogranin A
5-HIAA	5-hydroxyindoleacetic acid
CT	computed tomography
MRI	magnetic resonance imaging
PET	positron emission tomography
SPECT	single-photon emission computed tomography
SSTR-PET	somatostatin receptor PET
NANETS	North American Neuroendocrine Tumor Society
ENETS	European Neuroendocrine Tumor Society
NCI	national cancer institute
RFA	radiofrequency ablation
RHC	Right hemicolectomy
SSAs	somatostatin analogues
SSTR	somatostatin receptor
LAR	long-acting release
TTP	time to progression
PFS	progression-free survival
PRRT	peptide receptor radionuclide therapy
HR	hazard ratio
MDS	myelodysplastic syndrome
VEGF	vascular endothelial growth factor
PDGFRs	platelet-derived growth factor receptors
FGFRs	Fibroblast growth factor receptors
TKIs	tyrosine kinase inhibitors
CAPTEM	capecitabine and temozolomide
ORR	objective response rate
IP	Irinotecan cisplatin doublet
EP	platinum etoposide
CI	confidence interval
RR	relative risk
OS	overall survival